Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Yoshiki Bessho of Suzuken Elected New FJPWA President
June 8, 2009
- Taisho Launches RiUP X5 Hair Growth Stimulator for Men
June 8, 2009
- CMIC: Semi-Annual Sales Up 14.4% Driven by CRO Business
June 8, 2009
- Switch OTC Drugs Based on Vidarabine Recommended for Approval
June 8, 2009
- EPS: Strong CRO Business Pushes Up Sales 11.6%
June 8, 2009
- Council on Online Sale of OTC Drugs Fails to Reach a Consensus
June 8, 2009
- BUSINESS NEWS IN BRIEF
June 8, 2009
- Kenko.com, Wellnet Sue Korosho Claiming that Ministerial Ordinance Goes against Law
June 8, 2009
- Initiate Policies that Attract R&D: PhRMA Chairman D. Brennan
June 8, 2009
- Schedule for Medical Materials System Reform Approved
June 8, 2009
- Ryukaikon Reviews One Year of Efforts to Improve Distribution Business Practices
June 8, 2009
- Encouraging Results Obtained with Lurasidone in PIII Trial: DSP
June 8, 2009
- Otsuka: Hyponatremia Drug Approved in the US
June 8, 2009
- Nippon Chemiphar: Profits Sinks as Sales of Generics Increase
June 1, 2009
- Draft Report on Proper Preparation, Use of Fertilized Human Embryos Approved
June 1, 2009
- Rush of Orders on Gargles, Masks
June 1, 2009
- Wakamoto: Profits Down due to Poor Stock Management
June 1, 2009
- Champix Cuts Lifetime Medical Spending by ¥30,000
June 1, 2009
- Average Operating Profit Rate Down to 0.38% for Top-Four Wholesalers
June 1, 2009
- Teijin: Pharma & HHC Business Remains Bullish
June 1, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…